In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and participation in clinical trials. We recently asked Nicolas Kirchuk (NK), CEO and co-founder of Biomakers, and Isagani Chico (IC), MD, VP, global …
4 emerging trends to watch in immunotherapy clinical trials
Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies …
European Society for Medical Oncology: Understanding barriers to accessible cancer care
The European Society for Medical Oncology (ESMO) recently held its first in-person congress since the COVID-19 pandemic. The conference, held in Paris, brought together more than 22,000 attendees to share and discuss the latest evidence and issues in cancer care. A common thread running through the congress program was ESMO’s …
Cell and Gene Therapy Answers: Bioanalytical support for cell and gene therapy
Your source for answers to the complex challenges of cell and gene therapy development. We recently spoke with Daniel Sikkema, executive director of global immunochemistry at Labcorp drug development, regarding bioanalytical support for cell and gene therapy modalities. He shared some of the current challenges in cell and gene therapy, …
Cell & Gene Therapy Answers: Preclinical oncology
Your source for answers on how to assess the preclinical efficacy of cell therapies. Watch the video > As the landscape of cell therapy continues to evolve, so are the tools to assess the efficacy of cell therapy in the preclinical space. To better understand Labcorp’s preclinical oncology role in …
The evolving perspective on the DCT model: Broader application and utility – March 2022
Welcome to the March Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. This month, we will touch on a few things that all have a common theme: the expansion of DCTs into new therapeutic areas, trial phases and geographies. We will start with a look back at our recent webinar …
Technologies, tools and processes to support patient-centric oncology trials
There is a gap between the number of patients needed to participate in new cancer trials and the number who give consent to take part. Decentralized clinical trials (DCTs) are helping to address this gap by increasing the reach of clinical studies beyond conventional research sites. DCTs provide an opportunity …
Utilization of Radiation in the Preclinical Oncology Setting
The American Cancer Society estimates that in 2017 over 1.6 million people will be diagnosed with non-skin cancers in the United States. It is known that more than 50% of all cancer patients will receive some sort of radiation therapy as part of their treatment plan. Why is it then …